{"id":925400,"date":"2026-01-08T09:46:25","date_gmt":"2026-01-08T14:46:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-and-komodo-health-partner-to-build-the-worlds-most-complete-longitudinal-rare-disease-dataset\/"},"modified":"2026-01-08T09:46:25","modified_gmt":"2026-01-08T14:46:25","slug":"genedx-and-komodo-health-partner-to-build-the-worlds-most-complete-longitudinal-rare-disease-dataset","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-and-komodo-health-partner-to-build-the-worlds-most-complete-longitudinal-rare-disease-dataset\/","title":{"rendered":"GeneDx and Komodo Health Partner to Build the World\u2019s Most Complete Longitudinal Rare Disease Dataset"},"content":{"rendered":"

<\/p>\n

GeneDx and Komodo Health Partner to Build the World\u2019s Most Complete Longitudinal Rare Disease Dataset<\/b><\/p>\n

GeneDx\u2019s Infinity\u2122 will leverage insights from Komodo\u2019s Healthcare Map\u00ae<\/sup> to unlock<\/i>faster health economics and outcomes research (HEOR), biopharma innovation, and AI-driven discovery<\/i><\/p>\n

GAITHERSBURG, Md.–(BUSINESS WIRE<\/a>)–
\nGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, the leader in AI-powered healthcare intelligence. Through the partnership, GeneDx\u2019s Infinity\u2122 will leverage real-world patient insights from Komodo\u2019s Healthcare Map\u00ae<\/sup>, to create the most comprehensive, longitudinal dataset for rare disease. The collaboration will unlock a new level of visibility into how rare diseases are diagnosed, managed, and treated across the full patient journey.<\/p>\n

\nGeneDx Infinity is the world\u2019s largest rare disease genomic dataset, built on more than 25 years of real-world clinical experience. It includes more than 2.5 million genetic tests enriched for rare disease and over 7 million phenotypic data points, with more than half of individuals representing non-European ancestry \u2013 making it one of the most diverse and representative rare disease datasets available today. GeneDx Infinity powers the #1 genomic test for rare disease, using world-class clinical interpretation and continuously learning AI to sharpen diagnoses and expand insight with every patient.<\/p>\n

\nKomodo\u2019s Healthcare Map is the industry\u2019s most authoritative and highest-fidelity view into the healthcare journeys of over 330 million de-identified patients. This collaboration will connect genomic and phenotypic insights from GeneDx with Komodo\u2019s Healthcare Map, including the Komodo Research Dataset which includes insights from open and closed claims based events for patients with Medicare, Medicaid, and commercial insurance. The Komodo Research Dataset includes diagnoses, procedures, encounters, payer segments, and Komodo-populated imputed allowed amounts. By leveraging these patient insights, GeneDx Infinity goes beyond diagnosis to illuminate real-world care pathways, outcomes, utilization, and unmet needs at an unprecedented scale.<\/p>\n

\n\u201cGeneDx Infinity is redefining what\u2019s possible in rare disease,\u201d said Lisa Gurry, Chief Business Officer at GeneDx. \u201cBy integrating patient insights from Komodo\u2019s Healthcare Map with our unmatched genomic and phenotypic data, we are creating the most comprehensive longitudinal view of rare disease to date. This partnership accelerates HEOR, advances biopharma innovation, and brings us closer to a future where patients get answers \u2013 and access to effective therapies \u2013 faster than ever before.\u201d<\/p>\n

\nTogether, GeneDx and Komodo will enable biopharma companies and researchers across healthcare to move faster and more confidently across the full life cycle of innovation \u2014 from discovery and development to access and outcomes \u2014 while upholding the highest standards of privacy, security, and ethical data use. All data integrations and analysis will be conducted using de-identified, privacy-preserving methodologies to ensure regulatory compliance and protect patient confidentiality.<\/p>\n

\n\u201cTo meaningfully improve outcomes in rare disease, we must create a truly connected view of genomic data, clinical practice, and real\u2011world evidence,\u201d said Miles Ennis, Chief Operating Officer, Komodo Health. \u201cOur partnership with GeneDx underscores Komodo\u2019s commitment to setting a new standard for rare disease research by delivering actionable intelligence that enables organizations to identify patients earlier, close gaps in care, and drive impact at scale.\u201d<\/p>\n

\nThe combined dataset will support high-impact use cases, including real-world evidence generation (RWE) for:<\/p>\n